1 | antagonists | 4,413 |
2 | agonists | 3,222 |
3 | modulators | 609 |
4 | modulator | 575 |
5 | superfamily | 248 |
6 | agonism | 127 |
7 | dihydrochloride | 108 |
8 | mimetics | 84 |
9 | adrenoceptors | 51 |
10 | beta-antagonists | 14 |
11 | inh-nf | 14 |
12 | macroglobulin | 11 |
13 | γ2 | 7 |
14 | adrenergics | 5 |
15 | antagonisms | 5 |
16 | c2α | 5 |
17 | pin2 | 5 |
18 | receptor-blocker | 5 |
19 | 8644 | 4 |
20 | antagonist* | 4 |
21 | nucis | 4 |
22 | ssnas | 4 |
23 | 18006 | 3 |
24 | azetidin-2-ones | 3 |
25 | diphosphocholine | 3 |
26 | izoenzymes | 3 |
27 | like1 | 3 |
28 | -c104 | 2 |
29 | 3',5'-bisphosphate | 2 |
30 | absence-ii | 2 |
31 | acetate- | 2 |
32 | adrenoblockers | 2 |
33 | agonist.a | 2 |
34 | agonists/analogues | 2 |
35 | anatagonists | 2 |
36 | antagonist-beta | 2 |
37 | arachidonyl-2'-chloroethylamide | 2 |
38 | cd94 | 2 |
39 | daf-12 | 2 |
40 | dph3 | 2 |
41 | erbb2/her2/neu | 2 |
42 | h1-receptors | 2 |
43 | n-methyl- | 2 |
44 | subunit-dependent | 2 |
45 | superagonists | 2 |
46 | tas2r131 | 2 |
47 | μ-receptors | 2 |
48 | -2-inhibitors | 1 |
49 | -aeds | 1 |
50 | -alterations | 1 |
51 | 3-o-phosphate | 1 |
52 | 3-o-β-d-glucopyranosylcampesterol | 1 |
53 | 6'-o-β-d-xylopyranoside | 1 |
54 | 98.57±0.03 | 1 |
55 | a/i-e | 1 |
56 | abcb1/b4 | 1 |
57 | absence-prothrombin | 1 |
58 | absence/antagonist-ii | 1 |
59 | abuse/addiction | 1 |
60 | analgesics-was | 1 |
61 | anatgonist | 1 |
62 | antagonist/warfarin | 1 |
63 | assay.there | 1 |
64 | blockers-was | 1 |
65 | cd111 | 1 |
66 | eaat1-4 | 1 |
67 | ebm=48 | 1 |
68 | et-ra | 1 |
69 | fpp®/day | 1 |
70 | kmo-upf | 1 |
71 | methyl-amino-alanine | 1 |
72 | misuse/noncompliance | 1 |
73 | mm2/j | 1 |
74 | mutants-was | 1 |
75 | muteins | 1 |
76 | non-ebm=47 | 1 |
77 | ox1r | 1 |
78 | penta-o-galloyl-β-d-glucose | 1 |
79 | powder/air | 1 |
80 | responsiveness.however | 1 |
81 | striatal/frontal | 1 |
82 | svct1/svct1 | 1 |
83 | use/frequency | 1 |
84 | users-yet | 1 |
1 | -2-inhibitors | 1 |
2 | -aeds | 1 |
3 | -alterations | 1 |
4 | -c104 | 2 |
5 | 18006 | 3 |
6 | 3',5'-bisphosphate | 2 |
7 | 3-o-phosphate | 1 |
8 | 3-o-β-d-glucopyranosylcampesterol | 1 |
9 | 6'-o-β-d-xylopyranoside | 1 |
10 | 8644 | 4 |
11 | 98.57±0.03 | 1 |
12 | a/i-e | 1 |
13 | abcb1/b4 | 1 |
14 | absence-ii | 2 |
15 | absence-prothrombin | 1 |
16 | absence/antagonist-ii | 1 |
17 | abuse/addiction | 1 |
18 | acetate- | 2 |
19 | adrenergics | 5 |
20 | adrenoblockers | 2 |
21 | adrenoceptors | 51 |
22 | agonism | 127 |
23 | agonist.a | 2 |
24 | agonists | 3,222 |
25 | agonists/analogues | 2 |
26 | analgesics-was | 1 |
27 | anatagonists | 2 |
28 | anatgonist | 1 |
29 | antagonisms | 5 |
30 | antagonist* | 4 |
31 | antagonist-beta | 2 |
32 | antagonist/warfarin | 1 |
33 | antagonists | 4,413 |
34 | arachidonyl-2'-chloroethylamide | 2 |
35 | assay.there | 1 |
36 | azetidin-2-ones | 3 |
37 | beta-antagonists | 14 |
38 | blockers-was | 1 |
39 | c2α | 5 |
40 | cd111 | 1 |
41 | cd94 | 2 |
42 | daf-12 | 2 |
43 | dihydrochloride | 108 |
44 | diphosphocholine | 3 |
45 | dph3 | 2 |
46 | eaat1-4 | 1 |
47 | ebm=48 | 1 |
48 | erbb2/her2/neu | 2 |
49 | et-ra | 1 |
50 | fpp®/day | 1 |
51 | h1-receptors | 2 |
52 | inh-nf | 14 |
53 | izoenzymes | 3 |
54 | kmo-upf | 1 |
55 | like1 | 3 |
56 | macroglobulin | 11 |
57 | methyl-amino-alanine | 1 |
58 | mimetics | 84 |
59 | misuse/noncompliance | 1 |
60 | mm2/j | 1 |
61 | modulator | 575 |
62 | modulators | 609 |
63 | mutants-was | 1 |
64 | muteins | 1 |
65 | n-methyl- | 2 |
66 | non-ebm=47 | 1 |
67 | nucis | 4 |
68 | ox1r | 1 |
69 | penta-o-galloyl-β-d-glucose | 1 |
70 | pin2 | 5 |
71 | powder/air | 1 |
72 | receptor-blocker | 5 |
73 | responsiveness.however | 1 |
74 | ssnas | 4 |
75 | striatal/frontal | 1 |
76 | subunit-dependent | 2 |
77 | superagonists | 2 |
78 | superfamily | 248 |
79 | svct1/svct1 | 1 |
80 | tas2r131 | 2 |
81 | use/frequency | 1 |
82 | users-yet | 1 |
83 | γ2 | 7 |
84 | μ-receptors | 2 |
1 | antagonist* | 4 |
2 | acetate- | 2 |
3 | n-methyl- | 2 |
4 | cd111 | 1 |
5 | tas2r131 | 2 |
6 | like1 | 3 |
7 | svct1/svct1 | 1 |
8 | daf-12 | 2 |
9 | pin2 | 5 |
10 | γ2 | 7 |
11 | 98.57±0.03 | 1 |
12 | dph3 | 2 |
13 | eaat1-4 | 1 |
14 | -c104 | 2 |
15 | 8644 | 4 |
16 | cd94 | 2 |
17 | abcb1/b4 | 1 |
18 | 18006 | 3 |
19 | non-ebm=47 | 1 |
20 | ebm=48 | 1 |
21 | agonist.a | 2 |
22 | et-ra | 1 |
23 | antagonist-beta | 2 |
24 | a/i-e | 1 |
25 | misuse/noncompliance | 1 |
26 | arachidonyl-2'-chloroethylamide | 2 |
27 | dihydrochloride | 108 |
28 | 6'-o-β-d-xylopyranoside | 1 |
29 | diphosphocholine | 3 |
30 | methyl-amino-alanine | 1 |
31 | assay.there | 1 |
32 | penta-o-galloyl-β-d-glucose | 1 |
33 | 3-o-phosphate | 1 |
34 | 3',5'-bisphosphate | 2 |
35 | inh-nf | 14 |
36 | kmo-upf | 1 |
37 | absence-ii | 2 |
38 | absence/antagonist-ii | 1 |
39 | mm2/j | 1 |
40 | striatal/frontal | 1 |
41 | 3-o-β-d-glucopyranosylcampesterol | 1 |
42 | agonism | 127 |
43 | absence-prothrombin | 1 |
44 | macroglobulin | 11 |
45 | antagonist/warfarin | 1 |
46 | abuse/addiction | 1 |
47 | ox1r | 1 |
48 | receptor-blocker | 5 |
49 | responsiveness.however | 1 |
50 | powder/air | 1 |
51 | modulator | 575 |
52 | ssnas | 4 |
53 | analgesics-was | 1 |
54 | blockers-was | 1 |
55 | mutants-was | 1 |
56 | adrenergics | 5 |
57 | mimetics | 84 |
58 | -aeds | 1 |
59 | izoenzymes | 3 |
60 | azetidin-2-ones | 3 |
61 | agonists/analogues | 2 |
62 | nucis | 4 |
63 | antagonisms | 5 |
64 | muteins | 1 |
65 | -alterations | 1 |
66 | adrenoblockers | 2 |
67 | modulators | 609 |
68 | -2-inhibitors | 1 |
69 | h1-receptors | 2 |
70 | μ-receptors | 2 |
71 | adrenoceptors | 51 |
72 | agonists | 3,222 |
73 | superagonists | 2 |
74 | anatagonists | 2 |
75 | antagonists | 4,413 |
76 | beta-antagonists | 14 |
77 | users-yet | 1 |
78 | subunit-dependent | 2 |
79 | anatgonist | 1 |
80 | erbb2/her2/neu | 2 |
81 | fpp®/day | 1 |
82 | use/frequency | 1 |
83 | superfamily | 248 |
84 | c2α | 5 |